Total Funding
1
41
Total FundingGrant raised
Growth Score
-28 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
187140
ICAgen, a biopharmaceutical company, develops novel orally-administered small molecule drugs that modulate ion channel targets.
P Kay Wagoner: Co-Founder- Mark Korb: CFO
About the Company
Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase
I multiple dose study in healthy volunteers for the treatment of asthma. The company also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders. Icagen has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma, Inc.; and Pfizer, Inc.
